BioSpace News Archive

Drug Development

Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy

Retrophin, Inc. announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often leads to end-stage renal disease

December 28, 2018
·
7 min read
Deals

Boston Scientific Exercises $325 Million Option to Buy Millipede

Boston Scientific is exercising its option to buy the remaining shares of Santa Rosa, Calif.-based Millipede. The original deal was entered into in January 2018, when Boston Scientific acquired $90 million shares with the option to buy the remaining $325 million, which the company did yesterday.

December 28, 2018
·
2 min read
·
Mark Terry
Deals

At the Eleventh Hour, Harpoon Therapeutics Signs up to Join the 2018 IPO Game

Harpoon initiated a Phase I trial for its lead candidate for prostate cancer earlier this summer.

December 28, 2018
·
2 min read
·
Alex Keown
Business

QurAlis Spins out Med Device Company EnClear to Target ALS

EnClear aims to develop a device that will continuously clear toxic proteins from cerebrospinal fluids.

December 28, 2018
·
3 min read
·
Alex Keown
Business

How Automation Will Bring BioPharma Research Into the 21st Century

As technology advances, more of it becomes automated. While some manufacturing industries have long utilized automation throughout their processes and product production, the biopharma industry is comparatively behind the times.

December 28, 2018
·
4 min read
·
Chelsea Weidman Burke
Drug Development

Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

Bio-Path Holdings, Inc. provides an update from several clinical development programs and a 2019 business overview

December 28, 2018
·
6 min read
Pharm Country

Investing Into R&D Pays off for Some of Biotech’s Biggest Companies

PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.

December 28, 2018
·
3 min read
·
Sasha Mortimer
Business

Are China’s CRISPR Clinical Trials Running off the Rails?

Follow-up investigations by the Wall Street Journal suggest that He Jiankui’s story may be just the tip of the iceberg of sloppy and unmonitored clinical trials using CRISPR in China.

December 28, 2018
·
4 min read
·
Mark Terry
FDA

Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)

First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa

December 28, 2018
·
12 min read
Business

Prof. Jackie Ying Receives 2018 Turkish Academy of Sciences Prize

Professor Jackie Y. Ying who heads A*STAR’s NanoBio Lab in Singapore has won the 2018 Turkish Academy of Sciences Academy Prize in Science and Engineering Sciences

December 28, 2018
·
5 min read